The ROR2 (Receptor tyrosine kinase-like orphan receptor 2) antibody is a research tool designed to detect and study the ROR2 protein, a member of the receptor tyrosine kinase (RTK) family. ROR2 plays critical roles in developmental processes, particularly in skeletal formation, cell polarity, and tissue morphogenesis, by mediating non-canonical Wnt signaling pathways (e.g., Wnt5a). Dysregulation of ROR2 is linked to genetic disorders such as Robinow syndrome and brachydactyly type B, as well as cancer progression, including metastasis in breast cancer, melanoma, and osteosarcoma.
ROR2 antibodies are widely used in research to investigate protein expression, localization, and function in cellular and disease models. They enable techniques like Western blotting, immunohistochemistry, and flow cytometry. In therapeutic contexts, ROR2 is explored as a potential target for antibody-drug conjugates (ADCs) or inhibitors to block oncogenic signaling. Recent studies highlight its role in tumor microenvironments and drug resistance, driving interest in ROR2-targeted therapies.
Commercial ROR2 antibodies vary in specificity, with validation required for cross-reactivity and batch consistency. Challenges remain in distinguishing ROR2 isoforms and optimizing detection in complex tissues. Ongoing research aims to clarify its dual roles as both a tumor suppressor and promoter, depending on cellular context, underscoring the importance of reliable antibodies in advancing ROR2-related biomedical discoveries.